Fig. 7From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cellsDocking of gedatolisib in the active drug binding site of ABCB1 and ABCG2. The best docked poses of gedatolisib with the residues of ABCB1 (a) and ABCG2 (b) homology modelBack to article page